These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 452843)

  • 1. Changing epidemiology of Parkinson's disease: predicted effects of levodopa treatment.
    Marttila RJ; Rinne UK
    Acta Neurol Scand; 1979 Mar; 59(2-3):80-7. PubMed ID: 452843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term responses of Parkinson's disease to levodopa therapy.
    Rinne UK; Sonninen V; Siirtola T; Marttila R
    J Neural Transm Suppl; 1980; (16):149-56. PubMed ID: 6776234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of Parkinson's disease.
    Rajput AH
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):156-9. PubMed ID: 6713314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
    Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.
    Sweet RD; McDowell FH
    Ann Intern Med; 1975 Oct; 83(4):456-63. PubMed ID: 1166978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom.
    Head J; Ben-Shlomo Y; Lees AJ
    Clin Neuropharmacol; 1998; 21(4):265-6. PubMed ID: 9704171
    [No Abstract]   [Full Text] [Related]  

  • 9. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease.
    Scigliano G; Musicco M; Soliveri P; Piccolo I; Girotti F; Giovannini P; Caraceni T
    Neurology; 1990 Feb; 40(2):265-9. PubMed ID: 2300246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mortality in Parkinson's disease and its modification by levodopa (author's transl)].
    Schneider E; Fischer PA; Jacobi P; Kolb R
    Fortschr Neurol Psychiatr; 1981 May; 49(5):187-92. PubMed ID: 7239405
    [No Abstract]   [Full Text] [Related]  

  • 13. Present morality in parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths.
    Diamond SG; Markham CH
    J Neural Transm; 1976; 38(3-4):259-69. PubMed ID: 956812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease in Taiwan: an analysis of 215 patients.
    Chia LG; Liu LH
    Neuroepidemiology; 1992; 11(3):113-20. PubMed ID: 1407246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Punding prevalence in Parkinson's disease.
    Miyasaki JM; Al Hassan K; Lang AE; Voon V
    Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
    Harris MA; Koehoorn M; Teschke K
    Parkinsonism Relat Disord; 2011 Jul; 17(6):464-9. PubMed ID: 21531606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
    Simioni AC; Dagher A; Fellows LK
    Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: progression and mortality.
    Hoehn MM
    Adv Neurol; 1987; 45():457-61. PubMed ID: 3825726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.